Trials / Completed
CompletedNCT03995680
Efficacy and Safety of a New Chewable Versus the Swallowable Tablet of Mebendazole Against Hookworm
Efficacy and Safety of a New Chewable Tablet of Mebendazole Versus the Swallowable, Standard Tablet of Mebendazole Against Hookworm Infections in Children: a Randomized Controlled Trial
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 397 (actual)
- Sponsor
- Swiss Tropical & Public Health Institute · Academic / Other
- Sex
- All
- Age
- 3 Years – 12 Years
- Healthy volunteers
- Accepted
Summary
The rational of this study is to provide evidence on the safety and efficacy of a new chewable tablet of mebendazole compared to the standard tablet in preschool- and school-aged children infected with hookworm.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Mebendazole | Treatment with one of the two formulations of mebendazole. The only difference between both arms is the type of formulation of the drug: chewable versus swallowable tablet. |
Timeline
- Start date
- 2019-07-12
- Primary completion
- 2019-10-09
- Completion
- 2019-10-09
- First posted
- 2019-06-24
- Last updated
- 2020-07-20
- Results posted
- 2020-07-20
Locations
1 site across 1 country: Tanzania
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03995680. Inclusion in this directory is not an endorsement.